Investigational drug · Phase 2
PRGN-2012
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PRGN-2012"
First trial start
2021
Mar 16, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRGN-2012", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Respiratory Papillomatosis
- Papillomavirus Infections
- Papillomaviridae
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "PRGN-2012" as an intervention, largest first.
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruiting
National Cancer Institute (NCI)NIH
NCT07756840 · 50 participants (planned) · Start Nov 24, 2026 · Primary completion Jul 1, 2029
Drug: PRGN-2012; Bevacizumab · For: Respiratory Recurrent Papillomatosis (RRP); Human Papillomavirus (HPV); Papillomavirus Infection and 3 more
Sites: Bethesda, Maryland
- Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisActive, not recruiting
Precigen, IncIndustry
NCT04724980 · 38 participants · Start Mar 16, 2021 · Primary completion Jun 5, 2024
Drug: PRGN-2012 - Phase I; Dose Level 1; PRGN-2012 - Phase I; Dose Level 2 and 1 more · For: Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Papillomaviridae
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis.
Cheng CM · Ann Pharmacother 2026
- The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis.
Baali MH, Neazy AA, Altalhi WA, et al. · J Voice 2026
- In Reference to A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis.
Hasan MA, Amjad H, Akhtar S, et al. · Laryngoscope 2026
- Emerging Therapeutic Strategies for HPV-Related Cancers: From Gene Editing to Precision Oncology.
Cakir MO, Kayhan G, Yilmaz B, et al. · Curr Issues Mol Biol 2025
- Disease Control and Voice Outcomes Following Treatment With PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis.
Kaskas A, Valdez J, Napier S, et al. · J Voice 2025
- PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.
Norberg SM, Valdez J, Napier S, et al. · Lancet Respir Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.